EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrative Mendelian Randomization and Multiomics Analysis Identifies CAF‐Derived Complement Factor B as a Prognostic Biomarker and Therapeutic Vulnerability in Breast Cancer

Hong Xiang iD, Na Ren iD, Ting Wang iD, Xueyan Zheng iD, Ziyu Kang iD, Yanjin Dong iD

Human Mutation · 2026-01 · 2026 (1)

DOI: 10.1155/humu/2179334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Mutation, online erschienen am 13.05.2026. Verfasst von Hong Xiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacy (Institute of TCM Health Industrial Technology), Shandong University of Traditional Chinese Medicine, Jinan, China, sdutcm.edu.…. Hauptthemen laut MEDLINE: Breast Neoplasms, Biomarkers, Tumor, Complement Factor B, Cancer-Associated Fibroblasts. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai University of Traditional Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Complement factor B (CFB), a key component of the alternative complement pathway, has been implicated in tumor‐related inflammation; however, its causal role and therapeutic relevance in breast cancer remain unclear. By integrating genetic epidemiology, multiomics transcriptomics analyses, and AI‐assisted drug prediction, we aimed to clarify the biological and clinical significance of CFB in breast cancer.

Results

Mendelian randomization analysis suggested a potential causal association between circulating CFB levels and breast cancer risk (OR = 1.048, 95% CI: 1.018–1.078, p = 0.001). Single‐cell transcriptomic analysis identified cancer‐associated fibroblasts (CAFs) as the primary cellular source of CFB within the tumor microenvironment. High CFB expression was significantly associated with advanced clinical stage, lymph node metastasis, and poor overall survival and was confirmed as an independent prognostic factor (HR = 2.35, 95% CI: 1.55–3.56, p < 0.001). Tumors with elevated CFB displayed immunosuppressive characteristics, including increased regulatory T cells and M2 macrophages, higher TIDE scores, and strong correlations with immune checkpoint molecules. AI‐based drug sensitivity prediction and validation analyses revealed that CFB‐high tumors exhibited enhanced sensitivity to PARP inhibitors. Additional mutation‐related bioinformatic analyses showed that CFB‐mutated tumors were associated with higher TMB, increased MSI‐H proportion, an immunosuppressive microenvironment, and enhanced predicted sensitivity to PARP inhibitors. Mechanistically, CFB expression strongly correlated with PARP1 ( R = 0.77), and CAF‐derived CFB enhanced olaparib‐induced DNA damage in TNBC models.

Conclusion

Through integrative traditional and AI‐driven approaches, this study supports CFB as a genetically associated risk protein with potential causal relevance and as a prognostic and therapeutic biomarker at both the expression and mutation levels in breast cancer. These findings provide a mechanistic and translational basis for precision therapy targeting CFB‐overexpressing tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBiomarkers, TumorComplement Factor BCancer-Associated FibroblastsMendelian Randomization AnalysisHumansFemalePrognosisMultiomicsTumor MicroenvironmentGene Expression Regulation, NeoplasticGene Expression Profiling

Stichwörter der Autor:innen

Mendelian randomizationPARP inhibitorsbreast cancercancer-associated fibroblastscomplement factor Bmultiomics integration

Substanzen

Biomarkers, TumorComplement Factor B

Autor:innen und Institutionen

  • Institute of Pharmacy (Institute of TCM Health Industrial Technology), Shandong University of Traditional Chinese Medicine, Jinan, China, sdutcm.edu.cn.
  • Pharmacy Department, Jinan Municipal People's Government Organs Outpatient Department, Jinan, China.
  • Department of Pharmacy, Jinan Second People's Hospital, Jinan, China, sdjneye.com.
  • Department of Laboratory Medicine, Jinan Second People's Hospital, Jinan, China, sdjneye.com.

ORCID-Profile: Hong Xiang, Na Ren, Ting Wang, Xueyan Zheng, Ziyu Kang, Yanjin Dong

Förderung

  • Shanghai University of Traditional Chinese Medicine

Zitieren

APA

Xiang, H., Ren, N., Wang, T., Zheng, X., Kang, Z., & Dong, Y. (2026). Integrative Mendelian Randomization and Multiomics Analysis Identifies CAF‐Derived Complement Factor B as a Prognostic Biomarker and Therapeutic Vulnerability in Breast Cancer. Human Mutation, 2026(1). https://doi.org/10.1155/humu/2179334

Vancouver

Xiang H, Ren N, Wang T, Zheng X, Kang Z, Dong Y. Integrative Mendelian Randomization and Multiomics Analysis Identifies CAF‐Derived Complement Factor B as a Prognostic Biomarker and Therapeutic Vulnerability in Breast Cancer. Human Mutation. 2026;2026(1). doi:10.1155/humu/2179334

BibTeX
@article{Xiang2026,
  author = {Xiang, Hong and Ren, Na and Wang, Ting and Zheng, Xueyan and Kang, Ziyu and Dong, Yanjin},
  title = {Integrative Mendelian Randomization and Multiomics Analysis Identifies CAF‐Derived Complement Factor B as a Prognostic Biomarker and Therapeutic Vulnerability in Breast Cancer},
  journal = {Human Mutation},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/humu/2179334}
}
Kostenlos starten →